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We investigate the effect of therapeutic procedure innovation in general on the longevity of all hospital
patients, i.e. patients with a variety of medical conditions.  The analysis is based on data on over one
million discharges from public and private hospitals in Western Australia (WA) during the period
2000-2007.  We can measure survival for a period as long as 8 years after admission, and we know
the date each procedure was added to the Medicare Benefits Schedule.
Estimates based on patient-level data indicate that therapeutic procedure innovation increased the life
expectancy of WA hospital patients  by almost 3 months between 2000 and 2007, controlling for the
patient’s age, sex, Diagnosis Related Group (DRG, over 600 categories), Aboriginal status, marital
status, insurance coverage (whether or not the patient had private insurance), postcode (over 400 postcodes),
year of hospital admission, and number of procedures performed..  Estimates based on longitudinal
DRG-level data also indicate that therapeutic procedure innovation increased the life expectancy of
WA hospital patients, but the implied increase may be smaller—about 2 months.  In either case, therapeutic
procedure innovation in WA hospitals appears to have been remarkably cost-effective, because it increased
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frl1@columbia.eduA number of previous studies have examined the effects of specific medical innovations, 
or innovations for specific medical conditions, on longevity and other patient outcomes.  For 
example, McGovern et al (1993) found that there were marked improvements in survival from 
1970 to 1985 among hospitalized stroke patients in the Twin Cities; these improvements 
occurred almost exclusively in the acute hospitalization phase, and improved medical care 
probably contributed to gains in survival.  Gockel et al (2008) argued that surgical therapy for 
esophageal carcinoma has undergone distinct changes over the past 20 years, and that these 
changes have led to a significantly more favorable long-term prognosis.  Ravi (2007) found that 
recent advances in the study and treatment of esophageal disorders allow for more accurate 
diagnosis of known esophageal disorders and have introduced previously unexplored disorders.  
Noble (2003) argued that “developments in neonatal technology continue to improve infant 
outcomes.”  Dobson (2003) found that “advances in medical technology account for a third of 
the reduction in road traffic deaths,” and Dobson (2002) found that “murder rates would be up to 
five times higher than they are but for medical developments over the past 40 years.”  However, 
Lameire et al (2009) found that, “overall, the major technological advances in dialysis have not 
yet been translated into longer patient survival.” 
  In this study, we will investigate the effect of therapeutic procedure innovation in general 
on the longevity of all hospital patients, i.e. patients with a variety of medical conditions.  The 
analysis will be based on data on over one million discharges from public and private hospitals in 
Western Australia (WA) during the period 2000-2007.  The hospital discharge data, contained in 
WA’s Hospital Morbidity Data Collection, are linked to WA Death Registration data up until 
March 1, 2008, so we can measure survival for a period as long as 8 years after admission.   
  Each hospital discharge record includes up to eleven procedure codes.  Since 1 July 1999, 
procedures have been coded using the International statistical classification of diseases and 
related health problems, 10th revision, Australian modification (ICD-10-AM). An important 
feature of ICD-10-AM was the addition of a classification of procedures based on the 2 
 
Commonwealth Medicare Benefits Schedule (MBS) of fees for health services.
1  The MBS is a 
listing of the Medicare services subsidized by the Australian government.
2  New procedures are 
added to the MBS each year.  In order to be included in the MBS, new medical technologies and 
procedures must be assessed by the Medical Services Advisory Committee (MSAC, 
http://www.msac.gov.au/), an independent scientific committee comprising individuals with 
expertise in clinical medicine, health economics and consumer matters.  The MSAC undertakes a 
rigorous and transparent assessment of new medical technologies in consultation with the 
applicant, and advises the Minister for Health and Ageing on whether new medical services 
should be publicly funded based on an assessment of their safety, effectiveness and cost 
effectiveness, using the best available evidence. 
  Each procedure in the MBS has a “start date,” i.e. the date the procedure was added to the 
MBS.  As of 1 November 2010, the MBS included 5756 items (procedures).  As shown in Figure 
1, 40% of the items included in the 1 November 2010 MBS were added by the end of 1992, 59% 
were added by the end of 1999, and 79% were added by the end of 2004.  Henceforth I will refer 
to the year in which a procedure was introduced into the MBS as the vintage of the procedure.
3 
  Innovation may be defined as “the introduction of a new idea, method or device.”
4  Our 
measures of innovation will be based on the mean vintage of the procedures used to treat a 
patient or group of patients.   
  We will investigate the effect of therapeutic procedure innovation
5 on hospital patient 
                                                            
1 It was a deliberate decision of the Casemix Implementation Project Board in 1995 to create this Australian 
procedure classification based on the fee schedule so that the classification of procedures in the public and private 
sectors, as well as in ambulatory situations, would be more consistent. The Australian procedure classification, 
known as the Medicare Benefits Schedule, Extended (MBS-E), is more specific than MBS, and is organised 
logically according to body system and site and includes a detailed index. Codes have been added for procedures not 
currently eligible for benefits, such as cosmetic surgery, obstetrics and allied health procedures.  See Roberts et al 
(1998). 
2 The Schedule is part of the wider Medicare Benefits Scheme managed by the Department of Health and Ageing 
and administered by Medicare Australia. 
3 According to the Merriam Webster dictionary, one definition of vintage is “a period of origin or manufacture (e.g. 
a piano of 1845 vintage)”.  http://www.merriam-webster.com/dictionary/vintage   
4 This is a synthesis of the two definitions of innovation provided by the Merriam Webster dictionary: “(1) the 
introduction of something new, and (2) a new idea, method, or device.”  http://www.merriam-
webster.com/dictionary/innovation  
5 About 90% of the procedures (and procedure fees) included in WA’s Hospital Morbidity Data Collection are 
accounted for by therapeutic (category 3) procedures.  Most of the remaining procedures are diagnostic imaging 
(category 5) procedures. 3 
 
 longevity in two different ways.  First, we will investigate the effect of therapeutic procedure 
vintage on patient survival using cross-sectional patient-level data.  We will control, in a very 
unrestrictive manner, for the patient’s age, sex, Diagnosis Related Group (DRG, over 600 
categories), Aboriginal status, marital status, insurance coverage (whether or not the patient has 
private insurance), postcode (over 400 postcodes), year of hospital admission, and number of 
procedures performed.   
These variables should control, to a very great extent, for the patient’s underlying health 
status and mortality risk prior to treatment.
6  Nevertheless, there may be unobserved 
heterogeneity of patients with respect to mortality risk, which could bias our estimates of the 
effect of therapeutic procedure vintage on patient survival.  However, both our own data and 
evidence from other studies suggest that the sickest patients tend to receive the newest 
treatments.  A regression of mean procedure vintage on all of the variables listed above indicates 
that (1) mean vintage is positively correlated with the number of procedures performed; (2) 
procedures used on uninsured patients are newer than those used on insured patients; and (3) 
procedures used on men are newer than those used on women.  Also, Hoover et al (2002) 
showed that mean annual medical expenditure  on persons aged 65 and older were over five 
times as high during the last year of life as they were during nonterminal years.  It is plausible 
that part of this expenditure differential is due to the use of newer, as well as more, procedures 
during the last year of life.  If the sickest patients tend to receive the newest treatments, our 
estimates of the effect of therapeutic procedure vintage on patient survival are likely to be 
conservative if we don’t adequately control for severity of illness. 
We believe that heterogeneous treatment of patients, controlling for their diagnoses, 
demographic characteristics, insurance coverage, and other factors, is primarily due to physician 
practice variation.  Wennberg (2004) argues that “unwarranted [treatment] variation—variation 
not explained by illness, patient preference, or the dictates of evidence-based medicine—is a 
ubiquitous feature of U.S. health care.”  This may also apply to Australia.  A large number of 
studies have documented the importance of unexplained variation in medical care.  Lee et al 
(2008) showed that “pediatric and adult transplant physicians differed significantly in their 
management strategies for chronic myeloid leukemia, acute and chronic graft-versus-host 
                                                            
6 For example, old men from poor regions receiving large number of procedures face higher mortality risk than 
young women from wealthy regions receiving fewer procedures. 4 
 
disease, and choice of graft source for patients with aplastic anemia. Among adult transplant 
physicians, there was little agreement on the patient factors favoring reduced intensity 
conditioning or myeloablative conditioning.”  DeSalvo et al (2000) reported “wide variation…in 
assignment
 of reappointment interval with mean return intervals…ranging from 2.2 to 20.5 
weeks. Sex was a significant provider independent
 variable…Female
 providers assigned earlier 
reappointment intervals for their
 patients.”  Solomon et al (2003) found that “established risk 
factors for NSAID-associated gastrointestinal toxicity were poor predictors of who was 
prescribed a selective COX-2 inhibitor; in contrast, physician prescribing preference was an 
important determinant.”  De Las Cuevas et al (2002) showed that “there is a remarkable degree 
of variation in antidepressant prescribing by psychiatrists and general practitioners; this is due to 
economic and social factors as much as to morbidity differences.”  Rochon et al (2007) found 
that “residents in facilities with high antipsychotic prescribing rates were about 3 times more 
likely than those in facilities with low prescribing rates to be dispensed an antipsychotic agent, 
irrespective of their clinical indication.”
7 
We will also investigate the effect of therapeutic procedure innovation on patient survival 
using longitudinal DRG-level data.  This approach enables us to determine whether DRGs that 
exhibited more procedure innovation (larger increases in procedure vintage) had greater 
increases in patient survival, ceteris paribus.  Estimates based on longitudinal DRG-level data are 
less subject to bias from unobserved patient heterogeneity than estimates based on cross-
sectional patient-level data.  Comparison of the two kinds of estimates can help us to assess the 
direction of bias, if any. 
  Section 2 describes the econometric models of patient survival we will estimate.  
Descriptive statistics are presented in Section 3.  Empirical results are presented in Section 4.  
The cost-effectiveness of therapeutic procedure innovation is assessed in Section 5.  Section 6 
provides a summary. 
  
                                                            
7 Using clinical and administrative data obtained from all facilities in a Department of Veterans Affairs integrated 
service network, Krein et al (2002) showed that there was variation in diabetes practice patterns at the primary care 
provider, provider group, and facility levels, and that the greatest amount of variance tended to be attributable to the 
facility level. 5 
 
2,  Econometric models of patient survival 
 
A.   Econometric models of patient survival based on cross-sectional patient-level data 
 
Dependent variables. We will estimate two types of models of patient survival using cross-
sectional patient-level data.  In the first type, the dependent variable is a binary variable 
indicating whether or not the patient survived a specified length of time, i.e. whether the patient 
was discharged alive (which we refer to as “0 years”), and whether the patient was alive 1, 2, 3, 
4, and 5 years after admission to the hospital.
8  These models will be of the form: 
survni=  vintagei +  Zi + i               (1)     
where  
survni   = 1 if patient i survived n years (n = 0, 1, …, 5) 
= 0 otherwise 
vintagei  = the vintage of therapeutic procedures performed on patient i 
Zi  = a vector of other attributes of patients i 
i    = a disturbance 
 
Since the dependent variable is a binary variable, we will estimate these models as probit 
models.   
In the second type of model, the dependent variable is the number of years the patient 
lived after being admitted to the hospital.  These models will be of the form: 
years_livedi=  vintagei +  Zi + i              (2)     
where  
years_livedi   = the number of years patient i lived after being admitted to the hospital 
 
If the patient did not die by 1 March 2008 (the Death Registration cut-off date), this 
variable is right censored.  I will account for this by using a statistical procedure (the SAS 
LIFEREG procedure) that fits parametric models to failure time data that can be uncensored, 
                                                            
8 Because the coverage of the WA Death Registration data ends on March 1, 2008, 1-year survival can be measured 
for patients hospitalized during 2000-2006, but 5-year survival can be measured only for patients hospitalized during 
2000-2002. 6 
 
right censored, left censored, or interval censored.  To reduce the degree of censoring, I will 
analyze people who were hospitalized during 2000-2004.  I will assume that the number of years 
the patient lived after being admitted to the hospital (or the number of years till death) has the 
Weibull distribution, one of the most commonly used distributions in failure time analysis.  The 
probability density function of a Weibull random variable X is: 
 
where k > 0 is the shape parameter and λ > 0 is the scale parameter of the distribution.
9  The 




  We assume that the scale parameter λ depends on patient characteristics X as follows: λ = 
exp( X). Hence ln  =  X, and ln(mean survival time) =  X + ln((1+(1/k))).  Therefore the 
estimated coefficient on a patient characteristic X1 indicates the percentage change in mean 
survival time attributable to a unit increase in X1. 
Explanatory variables. The explanatory variable of primary interest is the mean vintage of 
procedures used to treat the patient.  One potential measure of procedure vintage is the mean 
year in which the procedures performed on a patient commenced in the MBS: 
proc_yeari = p itempi item_start_yearp 
                                    p itempi 
where 
itempi = 1 if patient i was treated with procedure p 
          = 0 if patient i was not treated with procedure p 
 
                                                            
9 The shape parameter is what gives the Weibull distribution its flexibility. By changing the value of the shape 
parameter, the Weibull distribution can model a wide variety of data. If k = 1, the Weibull distribution is identical to 
the exponential distribution; if k = 2, the Weibull distribution is identical to the Rayleigh distribution; if k is between 
3 and 4 the Weibull distribution approximates the normal distribution. The Weibull distribution approximates the 
lognormal distribution for several values of k. 
10 See http://en.wikipedia.org/wiki/Weibull_distribution and http://www.engineeredsoftware.com/nasa/weibull.htm. 7 
 
item_start_yearp = the year procedure p commenced in the MBS 
 
However, as shown in Figure 1, item_start_year is, in effect, a “left-censored” variable: no items 
commenced before 1987, and a third of all items commenced in a single year (1991).  Therefore, 
the following may be a better measure of vintage: 
proc_post1995%i = p itempi item_post1995p 
                                            p itempi 
where 
item_post1995p = 1 if the year procedure p commenced in the MBS > 1995 
                          = 0 if the year procedure p commenced in the MBS < 1995 
 
Hence proc_post1995%i is the fraction of procedures used to treat patient i that were “new” 
procedures, where a procedure is considered “new” if it commenced in the MBS after 1995 
(approximately the median commencement year of items included in the MBS as of 1 November 
2010).   
In addition to procedure vintage, all of the models of patient survival we estimate using 
cross-sectional patient-level data will also include the following explanatory variables: dummy 
variables for the patient’s (single year of) age, sex, Diagnosis Related Group (DRG, over 600 
categories), Aboriginal status, marital status, insurance coverage (whether or not the patient has 
private insurance), postcode (over 400 postcodes), year of hospital admission, and number of 
procedures performed (1-11).   
 
B.  Econometric models of patient survival based on longitudinal DRG-level data 
 
To determine whether DRGs that exhibited more procedure innovation (larger increases 
in procedure vintage) had greater increases in patient survival, ceteris paribus, we will use 
longitudinal DRG-level data to estimate models of the following form: 
ln(surv%ndt/(1- surv%ndt)) =  proc_post1995%dt +  Zdt + d + t + dt   (3)   
where  
surv%0dt   = the fraction of patients discharged in year t in DRG d who were 8 
 
discharged alive (“survived 0 years”) 
surv%ndt  = the fraction of patients discharged in year t in DRG d who 
survived n years (n = 1, 2,…,5) 
proc_post1995%dt  = the fraction of procedures performed in year t in DRG d that were 
“new” procedures 
Zdt  = a vector of other attributes
11 of patients discharged in year t in 
DRG d 
d  = a fixed effect for DRG d 
t  = a fixed effect for year t 
dt    = a disturbance 
 
Eq. (3) will be estimated via weighted least-squares, where the weight is the number of patients 
discharged in year t in DRG d (Ndt).  We will allow for clustering of disturbances within DRGs.   
3.  Descriptive statistics 
  Descriptive statistics are shown in Table 1.  The number of discharges ranged between 
113 and 138 thousand per year.  The mean age of patients was about 64 years.  The average 
values of the 1-year, 3-year, and 5-year survival rates were 75.4%, 57.9%, and 48.7%, 
respectively.  Not surprisingly, these are far below the corresponding survival rates of the general 
population of Western Australia.  For example, according to the life table for Western Australia 
for the years 2001-2003, the 5-year survival rates of 64-year-old men and women in the general 
population were 93% and 96%, respectively.  What is perhaps more surprising is that survival 
rates of WA hospital patients declined during this period.
12  For example, the 3-year survival rate 
declined from 59.8% in 2000 to 55.9% in 2004.  This may be attributable to an increase in the 
average severity of illness of patients admitted to hospitals.  Patients with low illness severity 
may have been increasingly treated in an outpatient setting. 
  The average number of therapeutic procedures per patient remained constant (at about 
1.00) from 2000 to 2003, but declined 27% between 2003 and 2007.  This is entirely due to the 
fact that, for unknown reasons, the fraction of patients who had no therapeutic procedures 
increased from one-fourth during 2000-2003 to one half in 2007.
13 
                                                            
11 The other attributes are mean age, mean number of procedures performed, and fraction of patients with private 
insurance. 
12 Survival rates of the WA general population increased during this period.   
13 Among patients who had any therapeutic procedures, the mean number of procedures increased from 1.31 in 2003 
to 1.46 in 2007. 9 
 
  WA’s Hospital Morbidity Data Collection does not contain any cost information, but we 
can compute the cost of each patient’s therapeutic procedures (in 2010 dollars) by using the 
schedule fees contained in the 1 November 2010 MBS.  Due to the decline in the average 
number of therapeutic procedures per patient, therapeutic procedure schedule fees per patient 
declined.  But therapeutic procedure schedule fees per procedure increased from $268 in 2003 to 
$336 in 2007. 
  Both measures of procedure vintage increased during the sample period.  The fraction of 
therapeutic procedures with an item start year greater than 1995 increased from 8.2% in 2000 to 
14.6% in 2007. 
 
4.  Empirical results 
First we will present estimates of eq. (1).  To conserve space, we will provide complete 
estimates of just one model, and estimates of the key parameter of interest (, the procedure 
vintage coefficient) from 12 models.  Table 2 provides estimates of the model of the 2-year 
survival rate in which vintage is defined as proc_post1995% (the fraction of procedures that 
commenced in the MBS after 1995).   The estimates in this table indicate that the probability of 
being alive two years after admission was significantly higher for women and for people with 
private insurance, and inversely related to age and to the number of procedures performed on the 
patient, controlling for the patient’s DRG, postcode, year of admission, marital status, and 
aboriginal status.  The estimates also indicate that patients receiving newer procedures were 
significantly more likely to be alive two years after admission to the hospital. 
Table 3 presents estimates of from 12 different models: 6 survival intervals (0-5 years), 
and two alternative measures of therapeutic procedure vintage (proc_year and proc_post1995%).  
In model 1, the dependent variable is a dummy variable equal to 1 if the patient was alive when 
discharged from the hospital, and the regressor is the mean year in which the procedures 
performed on the patient commenced in the MBS.  The estimate of  is positive and significant, 
indicating that patients treated with newer procedures were more likely to be discharged alive.  
In models 2-6, the dependent variables are dummy variables indicating survival 1-5 years after 
admission to the hospital, and the same measure of procedure vintage is used.  The estimates of  
in all of these models are positive and significant.  Models 7-12 are similar to models 1-6, but the 10 
 
measure of procedure vintage is the fraction of procedures used to treat a patient that commenced 
in the MBS after 1995.  The estimate of  is not significant in model 7, but it is positive and 
highly significant (p-value < 0.0001) in models 8-12.   
As shown in Table 1, between 2000 and 2007, the fraction of therapeutic procedures that 
were “new” (commenced in the MBS after 1995) increased by .064, from 8.2% to 14.6%.  We 
can use the estimates of  in models 7 to 12 to assess how much therapeutic procedure 
innovation increased survival rates.  Let SURV_RATE denote the mean survival rate during the 
period, and F
-1( ) denotes the inverse of the standard normal cumulative distribution.  Then S0 = 
F [F
-1(SURV_RATE) –  (.064 / 2)] is the “predicted” survival rate if proc_post1995% had 
increased by .032 less than the actual increase; S1 = F [F
-1(SURV_RATE) +  (.064 / 2)] is the 
“predicted” survival rate if proc_post1995% had increased by .032 more than the actual increase; 
and S1 – S0 is the change in the survival rate attributable to therapeutic procedure innovation.  
The results of these calculations are shown in the following table. 
 
survival interval  S0 S 1 S 1 - S0 
alive at time of discharge  97.8% 97.8%  0.0% 
alive 1 year after admission  75.0% 75.8%  0.8% 
alive 2 years after admission  64.2% 65.2%  1.0% 
alive 3 years after admission  57.5% 58.4%  0.8% 
alive 4 years after admission  52.5% 53.2%  0.7% 
alive 5 years after admission  48.5% 49.0%  0.5% 
 
Model 8 implies that, ceteris paribus, therapeutic procedure innovation during the period 2000-
2007 increased the 1-year survival rate by .008, from 75.0% to 75.8%, and that it increased the 2-
year survival rate by .010, from 64.2% to 65.2%.  As noted above, survival rates of WA hospital 
patients declined during this period; our estimates indicate how much more they would have 
declined in the absence of therapeutic procedure innovation. 
  Now we will discuss estimates of eq. (2), in which the (right-censored) dependent 
variable is the number of years the patient lived after being admitted to the hospital.  This 
equation was estimated using data on 448,829 hospital discharges during the period 2000-2004.  
About half of these observations were right-censored, i.e. the patient did not die before 1 March 
2008.  The estimate of the Weibull shape parameter was significantly less than one (0.882, 11 
 
standard error = 0.0016), which indicates that the mortality rate decreases over time. This is not 
surprising, since the figures in Table 1 indicate that the probability of surviving 2 years, 
conditional on surviving one year (85.8% = 64.7% / 75.4%) is higher than the (unconditional) 
probability of surviving one year (75.4%). 
  When eq. (2) is estimated using proc_post1995% as the vintage measure, the coefficient 
on this variable is positive and highly significant:  
Estimate StdErr  ChiSq  ProbChiSq
0.383 0.019 399.5  0.0000
 
This indicates that the mean time till death of a patient treated with only old procedures was 32%  
(= exp(-0.383)) lower than the mean time till death of a patient treated with only new procedures, 
controlling for all of the covariates.  The estimate also implies that the 2000-2007 increase in 
proc_post1995%  increased the life expectancy of WA hospital patients by 2.4% (= 0.383 * 
.064).  The absolute increase (in months) in life expectancy of WA hospital patients attributable 
to therapeutic procedure innovation is equal to the percentage increase (2.4%) times the mean 
life expectancy.   We calculated mean life expectancy by estimating eq. (2) without any 
explanatory variables (only an intercept); in that model, mean life expectancy = λ (1+(1/k)).  
This implied that the mean life expectancy of WA hospital patients (whose mean age was 64.4) 
was 9.61 years.
14  Hence we estimate that, between 2000 and 2007, therapeutic procedure 
innovation increased the life expectancy of WA hospital patients by almost 3 months (0.234 
years = 2.4% * 9.61 years).  Between 2002 and 2008, the life expectancy at age 64 of the overall 
WA population increased by 0.9 years.
15  The annual rate of increase in the life expectancy of 
WA hospital patients attributable to therapeutic procedure innovation is about 22% as large as 
the annual rate of increase of life expectancy at age 64 of the overall WA population. 
  Now we will present estimates of models of patient survival based on longitudinal DRG-
level data.  Estimates of the coefficient  in eq. (3) are shown in Table 4.  Each estimate is from 
a different model.  All models include mean age, mean number of procedures performed, the 
fraction of patients with private insurance, DRG fixed effects, and year fixed effects.  Models 
                                                            
14 Mean life expectancy at age 64 of the overall WA population was 18.6 years for men and 22.1 years for women 
during 2001-2003.   
15 Due to right censoring of the survival data, during this period the change in the life expectancy of WA hospital 
patients can’t be reliably estimated. 12 
 
were estimated via weighted least-squares, where the weight is the number of patients discharged 
in year t in DRG d (Ndt).  Estimates allow for clustering of disturbances within DRGs.  In models 
13-18, the vintage measure is proc_year (the mean year in which the procedures performed 
commenced in the MBS).  The estimate of  is positive and significant (p-value < .05) in models 
13-16, indicating that DRGs with higher rates of therapeutic procedure innovation had larger 
increases in the odds of surviving until discharge and until 1, 2, and 3 years after admission.
16  In 
models 19-24, the other (we believe more reliable) vintage measure—proc_post1995% (the 
fraction of procedures that commenced in the MBS after 1995) —is used.  The estimate of  is 
positive and significant (p-value < .05) in models 19-23, except in model 20 (1-year survival 
rate), where it is marginally significant (p-value = .0767).   
Once again, we can use the estimates of  in models 19 to 23 to assess how much 
therapeutic procedure innovation increased survival rates.  In this case, we define S0 = 
1/(1+(1/exp [ln(SURV/(1- SURV)) –  (.064 / 2)])) as the “predicted” survival rate if 
proc_post1995% had increased by .032 less than the actual increase; S1 = 1/(1+(1/exp 
[ln(SURV/(1- SURV)) +  (.064 / 2)])) as the “predicted” survival rate if proc_post1995% had 
increased by .032 more than the actual increase; and S1 – S0 as the change in the survival rate 
attributable to therapeutic procedure innovation.  These calculations, and a comparison of them 
with the corresponding calculations based on patient-level data, are shown below. 
   patient level  DRG level 
survival interval  S0 S 1 S 1 - S0 S 0 S 1 S 1 - S0 
alive at time of discharge  97.8%  97.8%  0.0%  97.8%  97.9%  0.2% 
alive 1 year after admission  75.0%  75.8%  0.8%  75.2%  75.6%  0.4% 
alive 2 years after admission  64.2%  65.2%  1.0%  64.3%  65.0%  0.7% 
alive 3 years after admission  57.5%  58.4%  0.8%  57.6%  58.3%  0.8% 
alive 4 years after admission  52.5%  53.2%  0.7%  52.6%  53.0%  0.4% 
alive 5 years after admission  48.5%  49.0%  0.5% 
 
In three cases, the estimate of the increase in the survival rate attributable to therapeutic 
procedure innovation based on longitudinal DRG-level data is smaller than the estimate based on 
patient-level data.  In one case (the three-year survival rate), the two estimates are the same, and 
                                                            
16 As shown in Table 1, the 4-year survival rate can only be measured during 2000-2003, and the 5-year survival rate 
can only be measured during 2000-2002. 13 
 
in one case (survival until discharge), the estimate based on longitudinal DRG-level data is 
larger.   
Estimates of the survival-time model (eq. (2)), which was based on patient-level data, 
indicated that, between 2000 and 2007, therapeutic procedure innovation increased the life 
expectancy of WA hospital patients by almost 3 months.  The estimate of the increase in the 2-
year survival rate attributable to therapeutic procedure innovation based on longitudinal DRG-
level data is 30% smaller than the corresponding estimate based on patient-level data, so 
therapeutic procedure innovation may have increased the life expectancy of WA hospital patients 
by a smaller amount: about 2 months.   
5.  Cost-effectiveness of therapeutic procedure innovation 
In addition to estimating the longevity benefit of therapeutic procedure innovation, it is 
worthwhile to estimate the cost of this innovation, and the ratio of the two: the incremental cost-
effectiveness ratio (ICER). 
ICER =  PROC_COST  =  PROC_COST /  PROC_POST1995%   
                        LE                         LE /  PROC_POST1995%   
 
where PROC_COST  denotes the cost of therapeutic procedures and LE denotes life expectancy.  
We estimate the cost of each patient’s therapeutic procedures (in 2010 dollars) by using the 
schedule fees contained in the 1 November 2010 MBS: 
PROC_COSTi = p itempi schedule_feep 
 
where 
itempi = 1 if patient i was treated with procedure p 
          = 0 if patient i was not treated with procedure p 
 
schedule_feep = the fee for procedure p in the 1 November 2010 MBS 
 
To estimate the effect of therapeutic procedure innovation on cost, we can estimate an equation 
similar to eq. (1), in which the dependent variable is the (log of) the patient’s procedure cost: 14 
 
ln(PROC_COSTi) =  PROC_POST1995%i +  Zi + i             (4)     
The estimate of  in eq. (4) is 0.426 (t-value = 112.6).  The cost of procedures performed on 
patients receiving new procedures is higher than the cost of procedures performed on patients 
receiving old procedures.  However, the percentage increase in procedure cost attributable to the 
2000-2007 increase in PROC_POST1995% is quite small: 2.7% (= 0.426 * 6.4%).  Among 
people who had positive procedure cost, mean procedure cost per hospital discharge during 
2000-2004 was $367.  Therefore, therapeutic procedure innovation is estimated to have increased 
mean procedure cost by only $10 (= 2.7% * $367).    
Therapeutic procedure innovation in WA hospitals during the period 2000-2007 appears 
to have been remarkably cost-effective: it increased the life expectancy of patients by 2-3 
months, and increased medical expenditure by a negligible amount.  This may be due in part to 
the fact that decisions about whether new medical services are publicly funded are based on an 
assessment of their safety, effectiveness and cost effectiveness, using the best available evidence. 
 
6.  Summary 
A number of previous studies have examined the effects of specific medical innovations, 
or innovations for specific medical conditions, on longevity and other patient outcomes.  In this 
study, we investigated the effect of therapeutic procedure innovation in general on the longevity 
of all hospital patients, i.e. patients with a variety of medical conditions.  The analysis was based 
on data on over one million discharges from public and private hospitals in Western Australia 
(WA) during the period 2000-2007.  The hospital discharge data, contained in WA’s Hospital 
Morbidity Data Collection, are linked to WA Death Registration data up until March 1, 2008, so 
we could measure survival for a period as long as 8 years after admission.  Measurement of 
procedure innovation was facilitated by the fact that hospital procedures are coded using the 
Commonwealth Medicare Benefits Schedule (MBS), and we know the date each procedure was 
added to the MBS. 
We investigated the effect of therapeutic procedure innovation on hospital patient 
longevity in two different ways.  First, we investigated the effect of therapeutic procedure 
innovation on patient survival using cross-sectional patient-level data.  We controlled, in a very 
unrestrictive manner, for the patient’s age, sex, Diagnosis Related Group (DRG, over 600 15 
 
categories), Aboriginal status, marital status, insurance coverage (whether or not the patient had 
private insurance), postcode (over 400 postcodes), year of hospital admission, and number of 
procedures performed.  We also investigated the effect of therapeutic procedure innovation on 
patient survival using longitudinal DRG-level data.  This approach enabled us to determine 
whether DRGs that exhibited more procedure innovation had greater increases in patient 
survival, ceteris paribus.   
Estimates based on patient-level data indicated that therapeutic procedure innovation 
increased the life expectancy of WA hospital patients (whose mean life expectancy was about 10 
years) by almost 3 months between 2000 and 2007.  (Between 2002 and 2008, the life 
expectancy of the overall WA population of the same mean age (64) increased by about 11 
months.)  Estimates based on longitudinal DRG-level data also indicated that therapeutic 
procedure innovation increased the life expectancy of WA hospital patients, but the implied 
increase may be smaller—about 2 months.  In either case, therapeutic procedure innovation in 
WA hospitals appears to have been remarkably cost-effective, because it increased the cost of 
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start year > 
1995
2000 113,205 97.8% 76.9% 66.9% 59.8% 54.8% 50.4% 63.6 54% 34% 0.97 26% $279 109,462 1992.17 8.2%
2001 119,216 97.8% 76.7% 66.1% 58.9% 53.8% 49.1% 63.9 54% 37% 0.97 25% $270 115,169 1992.21 8.5%
2002 126,190 97.8% 75.8% 65.1% 58.4% 52.2% 46.9% 64.3 54% 39% 0.98 24% $269 123,922 1992.29 9.5%
2003 128,123 97.9% 75.6% 65.2% 57.1% 50.9% 64.2 53% 40% 1.00 23% $269 128,461 1992.39 10.4%
2004 131,472 97.9% 75.6% 63.6% 55.9% 64.5 54% 40% 0.90 34% $262 117,670 1992.38 11.7%
2005 138,362 97.9% 73.8% 61.8% 64.8 54% 41% 0.78 45% $248 108,399 1992.37 13.2%
2006 136,877 97.9% 73.6% 64.9 54% 42% 0.76 48% $249 104,118 1992.43 14.3%
2007 121,403 97.8% 64.5 55% 41% 0.73 50% $247 89,152 1992.40 14.6%
2000-2007 1,014,848 97.8% 75.4% 64.7% 57.9% 52.8% 48.7% 64.4 54% 39% 0.88 35% $261 896,353 1992.33 11.1%
Table 1
Descriptive statisticsParameter Level1 Estimate StdErr ChiSq ProbChiSq Parameter Level1 Estimate StdErr ChiSq ProbChiSq
proc_post1995% 0.405 0.015 729.76024 0.0000 Private  insurance No -0.108 0.005 575.9 0.0000
SEX Female 0.151 0.004 1190.445 0.0000 Private insurance Yes 0.000
SEX Male 0.000 Admission year 2000 0.106 0.008 198.6 0.0000
AGE 00 - 04 AGE 1.714 0.032 2833.3333 0.0000 Admission year 2001 0.112 0.007 226.7 0.0000
AGE 05 - 17 AGE 1.535 0.023 4307.702 0.0000 Admission year 2002 0.083 0.007 131.6 0.0000
AGE 18 - 24 AGE 1.341 0.030 1960.589 0.0000 Admission year 2003 0.112 0.007 246.4 0.0000
AGE 25 - 44 AGE 1.154 0.013 8244.2697 0.0000 Admission year 2004 0.043 0.007 35.6 0.0000
AGE 45 - 54 AGE 0.949 0.011 6949.4544 0.0000 Admission year 2005 0.000
AGE 55 - 64 AGE 0.797 0.011 5688.7773 0.0000 ABORIG Aboriginal and Torres -1.003 0.401 6.2 0.0125
AGE 65 - 74 AGE 0.571 0.010 3240.0956 0.0000 ABORIG Aboriginal not Torres  -1.237 0.298 17.3 0.0000
AGE 75 - 84 AGE 0.384 0.010 1545.4463 0.0000 ABORIG Other -1.172 0.297 15.6 0.0001
AGE 85 - 99 AGE 0.000 ABORIG Torres Strait Islander n 0.000
No. of procedures 1 0.229 0.133 2.9822589 0.0842 Marital status Divorced -0.024 0.010 5.3 0.0213
No. of procedures 2 0.163 0.133 1.510947 0.2190 Marital status Married (including de 0.007 0.006 1.3 0.2491
No. of procedures 3 0.089 0.133 0.4510063 0.5019 Marital status Never married 0.085 0.010 73.5 0.0000
No. of procedures 4 0.008 0.133 0.0033609 0.9538 Marital status Not Stated 0.009 0.015 0.3 0.5720
No. of procedures 5 -0.039 0.134 0.0855174 0.7700 Marital status Separated -0.166 0.015 122.7 0.0000
No. of procedures 6 -0.105 0.135 0.6024252 0.4377 Marital status Widowed 0.000
No. of procedures 7 -0.162 0.136 1.4172313 0.2339
No. of procedures 8 -0.159 0.138 1.3197098 0.2506
No. of procedures 9 -0.159 0.146 1.1797289 0.2774
No. of procedures 10 -0.140 0.163 0.7406225 0.3895
No. of procedures 11 0.000
Table 2
Estimates of the 2-year survival rate model 
The parameters are probit estimates of the model surv2i=  proc_post1995%i +  Zi + i.  The model also includes dummy variables for each
of over 600 Diagnosis Related Groups and for each of over 400 postcodes.Model dependent variable independent variable Estimate StdErr ChiSq ProbChiSq
1 alive at time of discharge proc_year 0.014 0.005 7.21 0.0072
2 alive 1 year after admission proc_year 0.066 0.002 798.46 0.0000
3 alive 2 years after admission proc_year 0.068 0.002 833.40 0.0000
4 alive 3 years after admission proc_year 0.054 0.002 473.13 0.0000
5 alive 4 years after admission proc_year 0.046 0.003 273.10 0.0000
6 alive 5 years after admission proc_year 0.033 0.003 100.68 0.0000
7 alive at time of discharge proc_post1995% -0.010 0.041 0.06 0.8074
8 alive 1 year after admission proc_post1995% 0.392 0.016 628.25 0.0000
9 alive 2 years after admission proc_post1995% 0.405 0.015 729.76 0.0000
10 alive 3 years after admission proc_post1995% 0.324 0.015 438.52 0.0000
11 alive 4 years after admission proc_post1995% 0.293 0.017 303.25 0.0000
12 alive 5 years after admission proc_post1995% 0.202 0.020 106.73 0.0000
Note: The estimates reported are estimates of the coefficient  in eq. (1): survni=  vintagei +  Zi + i.  
Each estimate is from a different probit model.  All models include dummy variables for the patient’s 
age, sex, Diagnosis Related Group (DRG, over 600 categories), Aboriginal status, marital status, 
insurance coverage (whether or not the patient has private insurance), postcode (over 400 postcodes), 
year of hospital admission, and number of procedures performed.
Estimates of models of patient survival based on cross-sectional patient-level data
Table 3Model dependent variable independent variable Estimate Stderr Z ProbZ
13 alive at time of discharge proc_year 0.207 0.040 5.216 0.0000
14 alive 1 year after admission proc_year 0.052 0.026 1.986 0.0470
15 alive 2 years after admission proc_year 0.075 0.027 2.786 0.0053
16 alive 3 years after admission proc_year 0.076 0.029 2.588 0.0097
17 alive 4 years after admission proc_year 0.026 0.015 1.710 0.0872
18 alive 5 years after admission proc_year 0.017 0.017 0.957 0.3384
19 alive at time of discharge proc_post1995% 1.240 0.443 2.799 0.0051
20 alive 1 year after admission proc_post1995% 0.315 0.178 1.770 0.0767
21 alive 2 years after admission proc_post1995% 0.475 0.160 2.959 0.0031
22 alive 3 years after admission proc_post1995% 0.507 0.154 3.295 0.0010
23 alive 4 years after admission proc_post1995% 0.252 0.109 2.317 0.0205
24 alive 5 years after admission proc_post1995% 0.174 0.127 1.372 0.1699
Table 4
Estimates of models of patient survival based on longitudinal DRG-level data
Note: The estimates reported are estimates of the coefficient  in eq. (3): ln(surv%ndt/(1- surv%ndt)) = 
proc_post1995%dt +  Zdt + d +t + dt.  Each estimate is from a different model.  All models include 
mean age, mean number of procedures performed, the fraction of patients with private insurance, DRG 
fixed effects, and year fixed effects.  Models were estimated via weighted least-squares, where the 
weight is the number of patients discharged in year t in DRG d (N dt).  Estimates allow for clustering of 
disturbances within DRGs.  